US6677487B2
(en)
|
2001-08-30 |
2004-01-13 |
Pharmacia Corporation |
α-haloenamine reagents
|
GB0126618D0
(en)
|
2001-11-06 |
2002-01-02 |
Novartis Ag |
Organic compounds
|
ES2192494B1
(es)
*
|
2002-03-27 |
2005-02-16 |
Consejo Superior De Investigaciones Cientificas |
Derivados de 1,2,4-triazol con propiedades cannabinoides.
|
US8829198B2
(en)
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
GB0223978D0
(en)
*
|
2002-10-15 |
2002-11-20 |
Novartis Ag |
Organic compound
|
US20050008699A1
(en)
*
|
2003-07-11 |
2005-01-13 |
Fred Wehling |
Effervescent glucosamine composition
|
AU2004298761A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Novartis Ag |
Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
|
GB0408078D0
(en)
*
|
2004-04-08 |
2004-05-12 |
Novartis Ag |
Organic compounds
|
JP2008500347A
(ja)
*
|
2004-05-24 |
2008-01-10 |
ニュー・ヨーク・ユニヴァーシティー |
高血糖症による血糖の急激な増加及び/又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
|
US9737511B2
(en)
*
|
2004-05-24 |
2017-08-22 |
Geoffrey C. GURTNER |
Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
|
RU2404776C2
(ru)
*
|
2005-01-28 |
2010-11-27 |
Новартис Аг |
ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2
|
JP2008530043A
(ja)
*
|
2005-02-10 |
2008-08-07 |
ノバルティス アクチエンゲゼルシャフト |
薬剤処分の改善法
|
KR101174966B1
(ko)
*
|
2005-05-31 |
2012-08-17 |
노파르티스 아게 |
철이 발병에 관여하는 간질환의 치료
|
CN101291655A
(zh)
*
|
2005-10-19 |
2008-10-22 |
诺瓦提斯公司 |
包含地拉罗司(deferasirox)的分散片
|
US7947673B2
(en)
|
2005-11-01 |
2011-05-24 |
Novartis Ag |
Method of scintigraphy
|
NZ572299A
(en)
*
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
BRPI0712020A2
(pt)
*
|
2006-05-23 |
2011-12-27 |
Novartis Ag |
mÉtodo de tratamento de hemocromatose hereditÁria
|
CL2007002026A1
(es)
|
2006-07-13 |
2008-06-06 |
Los Angeles Biomed Res Inst |
Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
|
US20100004303A1
(en)
*
|
2006-08-04 |
2010-01-07 |
Novartis Ag |
Treatment of endocrine dysfunction using iron chelators
|
US8153672B2
(en)
*
|
2006-11-29 |
2012-04-10 |
Novartis Ag |
Polymorphic forms of deferasirox (ICL670A)
|
EP1927591A1
(en)
*
|
2006-11-29 |
2008-06-04 |
Novartis AG |
Polymorphic Forms of Deferasirox (ICL670)
|
EP2108013A2
(en)
*
|
2007-01-29 |
2009-10-14 |
Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság |
Crystalline forms of deferasirox
|
AU2008250041A1
(en)
*
|
2007-05-14 |
2008-11-20 |
Novartis Ag |
Use of iron chelator for the treatment of myocardial infarction
|
EP1994930A1
(en)
*
|
2007-05-22 |
2008-11-26 |
Novartis AG |
Triazol compounds for treating biofilm formation
|
WO2009016359A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Pliva Hrvatska D.O.O. |
New forms of deferasirox
|
US20090082412A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched deferasirox
|
EP2062572A1
(en)
|
2007-11-19 |
2009-05-27 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical compositions
|
CZ301873B6
(cs)
*
|
2008-01-30 |
2010-07-14 |
Farmak, A. S. |
Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
|
WO2009106824A2
(en)
*
|
2008-02-25 |
2009-09-03 |
Cipla Limited |
Pharmaceutical formulations
|
WO2009111611A2
(en)
|
2008-03-05 |
2009-09-11 |
Proteotech Inc. |
Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
|
EP2291360A2
(en)
*
|
2008-04-21 |
2011-03-09 |
Actavis Group PTC ehf. |
Solid state forms of deferasirox salts and process for the preparation thereof
|
WO2009147529A1
(en)
*
|
2008-06-02 |
2009-12-10 |
Actavis Group Ptc Ehf |
Substantially pure deferasirox and processes for the preparation thereof
|
TWI488624B
(zh)
|
2008-09-22 |
2015-06-21 |
Nat University Corp Asahikawa Medical College |
鐵螯合劑、其製造方法及鐵離子之定量、捕捉方法
|
US10098857B2
(en)
|
2008-10-10 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
|
WO2010092419A1
(en)
|
2009-02-12 |
2010-08-19 |
Assistance Publique - Hopitaux De Paris |
Combined treatment of multiple sclerosis
|
JP2012520878A
(ja)
|
2009-03-19 |
2012-09-10 |
ロサンゼルス ビオメドイカル リサーチ インストイトウテ アト ハルボル‐ユーシーエルエー メドイカル センテル |
ムコール菌症、及びその他の真菌疾患の治療のためのワクチン組成物、及び方法
|
IT1398770B1
(it)
*
|
2009-07-22 |
2013-03-18 |
Bellacchio |
Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
|
WO2011021218A2
(en)
*
|
2009-08-12 |
2011-02-24 |
Msn Laboratories Limited |
Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
|
CA2781821A1
(en)
*
|
2009-12-07 |
2011-06-16 |
Mapi Pharma Limited |
Processes for the preparation of deferasirox, and deferasirox polymorphs
|
CA2805568A1
(en)
|
2010-07-08 |
2012-01-12 |
Ratiopharm Gmbh |
Oral dosage form of deferasirox
|
US8907083B2
(en)
|
2010-08-25 |
2014-12-09 |
Ramamohan Rao Davuluri |
Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
|
MX2013003522A
(es)
*
|
2010-10-01 |
2013-05-22 |
Cipla Ltd |
Composicion farmaceutica.
|
WO2012069946A1
(en)
*
|
2010-11-24 |
2012-05-31 |
Alembic Pharmaceuticals Limited |
Process for the preparation of deferasirox
|
US9796605B2
(en)
|
2011-01-14 |
2017-10-24 |
Disease Adsorption System Technologies Co., Ltd. |
Polymeric iron chelating agent
|
US20140316534A1
(en)
|
2011-10-14 |
2014-10-23 |
Photocure Asa |
Stent
|
EP2766049A1
(en)
|
2011-10-14 |
2014-08-20 |
Photocure ASA |
Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
|
US8822464B2
(en)
|
2011-11-28 |
2014-09-02 |
Boehringer Ingelheim International Gmbh |
N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
|
US8741892B2
(en)
|
2011-12-05 |
2014-06-03 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8642774B2
(en)
*
|
2011-12-08 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8846948B2
(en)
|
2011-12-13 |
2014-09-30 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8796467B2
(en)
|
2011-12-13 |
2014-08-05 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8716277B2
(en)
|
2011-12-14 |
2014-05-06 |
Boehringer Ingelheim International Gmbh |
Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
|
US8937176B2
(en)
|
2011-12-14 |
2015-01-20 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8883789B2
(en)
|
2011-12-14 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
|
US8889677B2
(en)
*
|
2012-01-17 |
2014-11-18 |
Boehringer Ingellheim International GmbH |
Substituted triazoles useful as mGlu5 receptor modulators
|
EP2964659B1
(en)
*
|
2013-03-06 |
2017-08-09 |
Biocon Limited |
Process for the preparation of deferasirox
|
SG10201807204YA
(en)
*
|
2013-03-08 |
2018-09-27 |
Novartis Ag |
Oral formulations of deferasirox
|
BR112015028257A2
(pt)
*
|
2013-05-10 |
2017-07-25 |
Cipla Ltd |
composição farmacêutica de baixa dose, método para tratar sobrecarga de ferro crônica, método para tratar toxicidade por chumbo, processo para preparar uma composição farmacêutica de baixa dose e processo
|
DE102013217390A1
(de)
|
2013-09-02 |
2015-03-05 |
Henkel Ag & Co. Kgaa |
Wasch- und Reinigungsmittel mit verbesserter Leistung
|
CN103454370B
(zh)
*
|
2013-09-11 |
2014-12-24 |
中美华世通生物医药科技(武汉)有限公司 |
一种利用hplc测定原料药中苯肼类化合物残留的方法
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
ES2734675T3
(es)
|
2014-05-20 |
2019-12-11 |
Sanovel Ilac Sanayi Ve Ticaret As |
Formulación de comprimido dispersable en agua que contiene deferasirox
|
EP2987482A1
(en)
|
2014-08-22 |
2016-02-24 |
Santa Farma Ilaç Sanayi A.S. |
Soluble and dispersible pharamaceutical deferasirox formulation
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
KR20160088965A
(ko)
|
2015-01-16 |
2016-07-27 |
대원제약주식회사 |
데페라시록스를 함유하는 현탁제
|
KR20170129802A
(ko)
|
2015-03-10 |
2017-11-27 |
아두로 바이오테크, 인코포레이티드 |
"인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법
|
CN104817538A
(zh)
*
|
2015-03-13 |
2015-08-05 |
东南大学 |
去铁斯诺-他克林金属离子鳌合剂及其药物用途
|
WO2016167729A1
(en)
|
2015-04-16 |
2016-10-20 |
Öğün Yusuf Toktamiş |
Dispersible tablets comprising deferasirox
|
EP3095443A1
(en)
|
2015-05-21 |
2016-11-23 |
Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical composition comprising deferasirox
|
WO2016203488A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Havaldar Freddy H |
Preparation of novel deferasirox analogues for antimalarial activity
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
KR101695970B1
(ko)
*
|
2015-07-31 |
2017-01-13 |
건일제약 주식회사 |
데페라시록스 함유 산제 및 그 제조방법
|
CN106554770B
(zh)
*
|
2015-09-29 |
2018-10-19 |
杭州杜易科技有限公司 |
一种三唑衍生物金属离子荧光探针及其制备方法和应用
|
TWI722031B
(zh)
|
2015-10-23 |
2021-03-21 |
瑞士商威佛(國際)股份有限公司 |
新穎的膜鐵運輸蛋白(ferroportin)抑制劑
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
US20190091204A1
(en)
|
2016-03-17 |
2019-03-28 |
Lupin Limited |
Compositions of deferasirox
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
WO2018059922A1
(en)
|
2016-09-30 |
2018-04-05 |
Synthon B.V. |
Pharmaceutical composition comprising deferasirox
|
JOP20180036A1
(ar)
|
2017-04-18 |
2019-01-30 |
Vifor Int Ag |
أملاح لمثبطات فروبورتين جديدة
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CZ2017255A3
(cs)
|
2017-05-04 |
2018-11-14 |
Zentiva, K.S. |
Filmem potažené tablety Deferasiroxu
|
WO2018208242A1
(en)
|
2017-05-10 |
2018-11-15 |
İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi |
Formulation of deferasirox tablet for oral suspension composition with better processability
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
US11331288B2
(en)
|
2017-09-14 |
2022-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conditioning irradiated tissue for increasing vascularity
|
EP3489692A1
(de)
|
2017-11-28 |
2019-05-29 |
Siemens Healthcare Diagnostics Products GmbH |
Prothrombinzeit-reagenz enthaltend einen eisenchelator
|
TR201722910A2
(tr)
|
2017-12-29 |
2019-07-22 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
|
KR20190110771A
(ko)
|
2018-03-21 |
2019-10-01 |
주식회사 한국팜비오 |
데페라시록스를 함유하는 소형 분산성 정제
|
CN108727287B
(zh)
*
|
2018-05-10 |
2020-10-27 |
东南大学 |
1,2,4-三唑类化合物及其盐和应用
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
GR1009592B
(el)
*
|
2018-07-03 |
2019-09-11 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
|
KR20200113116A
(ko)
|
2019-03-22 |
2020-10-06 |
주식회사 한국팜비오 |
데페라시록스를 포함하는 필름코팅정제
|
TW202102478A
(zh)
|
2019-04-01 |
2021-01-16 |
瑞士商威佛(國際)股份有限公司 |
新穎的鐵螯合物
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
IT202000000922A1
(it)
|
2020-01-20 |
2021-07-20 |
Cage Chemicals S R L |
Complessi di ferro e relativi sali come agenti di contrasto per MRI
|
EP4052698A1
(en)
|
2021-03-05 |
2022-09-07 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Film coated tablet comprising deferasirox
|
CN114276305B
(zh)
*
|
2021-12-28 |
2023-11-17 |
中山大学 |
一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
|
CN114478410B
(zh)
*
|
2022-03-31 |
2022-11-29 |
中山大学 |
一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
|
CN114591254B
(zh)
*
|
2022-03-31 |
2023-10-13 |
中山大学 |
一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用
|